Author Archives: donttradeourlivesaway

Doctors push Italy to demand generics for pricey hep c drugs

By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS, Uncategorized | Leave a comment

PhRMA slams Colombian efforts to cut price of cancer drug

By Suzanne Elvidge, BioPharma Dive| Sept 15, 2016 Dive Brief: Major trade organization PhRMA sharply criticized a decision by the Colombian government to reduce the price of Novartis’ cancer drug Gleevec (imatinib) in the country, calling the move a “harmful global precedent” … Continue reading

Posted in Compulsory Licensing, Drug prices, TRIPS plus, Uncategorized | Leave a comment

Sofosbuvir patent dispute- Delhi High Court update

A writ petition was filed before the Delhi High Court by I-MAK and DNP+, challenging the grant of patent to costly Hepatitis-C drug, Sofosbuvir. The first hearing for the case was expected take place on 13th September. However, the hearing has … Continue reading

Posted in Hepatitis C, Patent, Sofosbuvir, Uncategorized | Leave a comment

#TheNakedTruth about high medicine prices

The Naked Truth is a short video commissioned by the Access Campaign that aims to literally ‘strip’ away some of the untruths about the costs of developing new drugs. This demand for more financial transparency in drug development is one … Continue reading

Posted in Uncategorized | Leave a comment

UN High-Level Panel On Access To Medicines Issues “Landmark” Report

 BY Catherine Saez, Intellectual Property Watch| Sept 14, 2016 The long-awaited report by the United Nations High Level Panel on Access to Medicines was released today, making many recommendations. The panel calls for countries to embrace the policy space available … Continue reading

Posted in R&D, UN General Assembly HLM, Uncategorized | Leave a comment

UN panel blames capitalism, property rights for lack of access to medicines in poor nations

By Tom Giovanetti, Fox News | Sept 14, 2016 On Wednesday morning, a special United Nations High Level Panel on Access to Medicines released its findings—findings that have been long-awaited by the non-governmental organizations (NGOs) that drove its formation, and long-dreaded … Continue reading

Posted in UN General Assembly HLM, Uncategorized | Leave a comment

U.N. panel challenges market-based approach to drug R&D

By Ben Hirschler, Reuters | LONDON The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and … Continue reading

Posted in R&D, Uncategorized | Leave a comment